CL2021003388A1 - Inhibidores de la replicación del virus de inmunodeficiencia humana - Google Patents

Inhibidores de la replicación del virus de inmunodeficiencia humana

Info

Publication number
CL2021003388A1
CL2021003388A1 CL2021003388A CL2021003388A CL2021003388A1 CL 2021003388 A1 CL2021003388 A1 CL 2021003388A1 CL 2021003388 A CL2021003388 A CL 2021003388A CL 2021003388 A CL2021003388 A CL 2021003388A CL 2021003388 A1 CL2021003388 A1 CL 2021003388A1
Authority
CL
Chile
Prior art keywords
immunodeficiency virus
human immunodeficiency
inhibitors
virus replication
hiv
Prior art date
Application number
CL2021003388A
Other languages
English (en)
Spanish (es)
Inventor
Eric P Gillis
Christiana Iwuagwu
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71738195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021003388(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of CL2021003388A1 publication Critical patent/CL2021003388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2021003388A 2019-06-19 2021-12-17 Inhibidores de la replicación del virus de inmunodeficiencia humana CL2021003388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19

Publications (1)

Publication Number Publication Date
CL2021003388A1 true CL2021003388A1 (es) 2022-09-30

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003388A CL2021003388A1 (es) 2019-06-19 2021-12-17 Inhibidores de la replicación del virus de inmunodeficiencia humana

Country Status (33)

Country Link
US (2) US12129255B2 (cg-RX-API-DMAC7.html)
EP (1) EP3986561B1 (cg-RX-API-DMAC7.html)
JP (1) JP7628512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102932817B1 (cg-RX-API-DMAC7.html)
CN (2) CN114245795B (cg-RX-API-DMAC7.html)
AR (1) AR119174A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020295793B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025655A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021003388A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017479A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210664A (cg-RX-API-DMAC7.html)
DK (1) DK3986561T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974541T3 (cg-RX-API-DMAC7.html)
FI (1) FI3986561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240501T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065762T2 (cg-RX-API-DMAC7.html)
IL (1) IL288750B2 (cg-RX-API-DMAC7.html)
LT (1) LT3986561T (cg-RX-API-DMAC7.html)
MA (1) MA56526B1 (cg-RX-API-DMAC7.html)
MD (1) MD3986561T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021016149A (cg-RX-API-DMAC7.html)
MY (1) MY206712A (cg-RX-API-DMAC7.html)
PE (1) PE20220510A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553180A1 (cg-RX-API-DMAC7.html)
PL (1) PL3986561T3 (cg-RX-API-DMAC7.html)
PT (1) PT3986561T (cg-RX-API-DMAC7.html)
RS (1) RS65304B1 (cg-RX-API-DMAC7.html)
SI (1) SI3986561T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400153T1 (cg-RX-API-DMAC7.html)
TW (1) TWI850403B (cg-RX-API-DMAC7.html)
UA (1) UA128967C2 (cg-RX-API-DMAC7.html)
UY (1) UY38755A (cg-RX-API-DMAC7.html)
WO (1) WO2020254985A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12415771B2 (en) 2019-06-19 2025-09-16 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
AU2020358156B2 (en) * 2019-10-01 2024-06-06 Janssen Sciences Ireland Unlimited Company Method for treating HIV with cabotegravir and rilpivirine
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
WO2021176366A1 (en) * 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP4135702B1 (en) * 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2022362855B2 (en) * 2021-10-13 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL364279A1 (en) 2001-02-02 2004-12-13 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
WO2018045150A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12415771B2 (en) 2019-06-19 2025-09-16 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Also Published As

Publication number Publication date
HRP20240501T1 (hr) 2024-07-05
JP2022537047A (ja) 2022-08-23
UA128967C2 (uk) 2024-12-11
MX2021016149A (es) 2022-05-18
MA56526B1 (fr) 2024-05-31
MD3986561T2 (ro) 2024-06-30
PH12021553180A1 (en) 2022-11-07
RS65304B1 (sr) 2024-04-30
AU2020295793A1 (en) 2022-01-20
PE20220510A1 (es) 2022-04-07
MA56526A (fr) 2022-04-27
UY38755A (es) 2020-11-30
EP3986561A1 (en) 2022-04-27
CN119039288A (zh) 2024-11-29
LT3986561T (lt) 2024-04-25
TWI850403B (zh) 2024-08-01
AU2020295793B2 (en) 2023-07-06
WO2020254985A1 (en) 2020-12-24
SI3986561T1 (sl) 2024-04-30
IL288750B1 (en) 2024-12-01
PT3986561T (pt) 2024-03-15
CO2021017479A2 (es) 2022-04-19
US20210323967A1 (en) 2021-10-21
ES2974541T3 (es) 2024-06-27
US12129255B2 (en) 2024-10-29
KR102932817B1 (ko) 2026-03-04
IL288750B2 (en) 2025-04-01
IL288750A (en) 2022-02-01
TW202115055A (zh) 2021-04-16
EP3986561B1 (en) 2024-02-14
CR20210664A (es) 2022-01-21
JP7628512B2 (ja) 2025-02-10
CN114245795B (zh) 2024-08-06
BR112021025655A2 (pt) 2022-02-01
AR119174A1 (es) 2021-12-01
US20250019383A1 (en) 2025-01-16
HUE065762T2 (hu) 2024-06-28
DK3986561T3 (da) 2024-03-04
SMT202400153T1 (it) 2024-05-14
CA3143136A1 (en) 2020-12-24
CN114245795A (zh) 2022-03-25
KR20220024608A (ko) 2022-03-03
MY206712A (en) 2025-01-03
PL3986561T3 (pl) 2024-06-10
FI3986561T3 (fi) 2024-05-02

Similar Documents

Publication Publication Date Title
AR119174A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
MX2015011478A (es) Compuestos de amida para el tratamiento de vih.
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2021000329A1 (es) Compuestos útiles en terapia del vih
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2022002405A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2025016290A2 (es) Compuestos anti-vih
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018000251A2 (pt) composto, composição, e, método para tratar a infecção pelo hiv.
BR112018000179A2 (pt) composto, composição, e, método para tratar a infecção pelo hiv.
DOP2021000028A (es) Formulaciones de dendrímeros